Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.
J Immunol
; 205(9): 2342-2350, 2020 11 01.
Article
in English
| MEDLINE | ID: covidwho-745208
ABSTRACT
The scale of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has thrust immunology into the public spotlight in unprecedented ways. In this article, which is part opinion piece and part review, we argue that the normal cadence by which we discuss science with our colleagues failed to properly convey likelihoods of the immune response to SARS-CoV-2 to the public and the media. As a result, biologically implausible outcomes were given equal weight as the principles set by decades of viral immunology. Unsurprisingly, questionable results and alarmist news media articles have filled the void. We suggest an emphasis on setting expectations based on prior findings while avoiding the overused approach of assuming nothing. After reviewing Ab-mediated immunity after coronavirus and other acute viral infections, we posit that, with few exceptions, the development of protective humoral immunity of more than a year is the norm. Immunity to SARS-CoV-2 is likely to follow the same pattern.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Immunity, Humoral
/
Betacoronavirus
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
English
Journal:
J Immunol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS